HOME >> BIOLOGY >> NEWS
University Of Kentucky Researcher Awarded MERIT Extension For Study Of Third World Killer

LEXINGTON, KY (Sept. 21, 1998) - Salvatore Turco, Ph.D., professor of biochemistry, University of Kentucky College of Medicine, has received a five-year extension on a National Institutes of Health (NIH) Method to Extend Research in Time (MERIT) award. The National Institute of Allergy and Infectious Diseases at the NIH has awarded Turco $1,583,700 to continue his study, "Glycoconjugates of Leishmania."

Leishmania donovani, a one-cell parasite, is one of the world's major pathogens. It afflicts 10 to 20 million people in Mediterranean and Third World countries. The parasite is transmitted by sand flies and results in the disease called leishmaniasis. Leishmaniasis, which often results in death, is a problem for residents, travelers, and U.S. soldiers stationed in the Middle East. It was a particular issue during Desert Storm, Turco said. Symptoms include sores, high fever and severe disfigurement. There are only antiquated drugs used for cures and preventive measures, despite scientists' understanding of the biology of the parasite's attack on the human body.

"We are trying to determine how the parasite survives in the human host," Turco said. "We suspect there is something unusual about the Leishmania cell surface that we feel is responsible for the parasite to invade the body and survive with impunity."

Leishmania's cell surface contains a complex molecule made up of sugar, fat and phosphate, called a lipophosphoglycan, that is used for defensive purposes. The molecule prevents the host animal's white cells, called macrophages, from being activated and attacking the parasite. Without the lipophosphoglycan, the parasite is destroyed by macrophages.

Researchers hope that the molecule might play a key role in creating treatments or preventive therapies for leishmaniasis.


'"/>

Contact: Kim Cumbie
krcumb0@pop.uky.edu
(606) 323-6363
University of Kentucky Medical Center
22-Sep-1998


Page: 1

Related biology news :

1. Indiana University, EPA to study airborne PCBs
2. University of Alberta researcher looks for clues to mysterious disease
3. Northeastern University receives $12.4 million NSF grant for creation of nanomanufacturing institute
4. Washington University in St. Louis leads group studying aging process
5. Tufts University establishes $4 million dollar tissue engineering resource center
6. Case for IBD combination therapy comes from research at Baylor, MIT and Hebrew University
7. As informatics grows, Indiana University helps set research agenda
8. University of Arizona licenses patent for natural fungicide
9. Washington University in St. Louis plays key role in sequencing moss genome
10. University of Pittsburgh receives $10 million grant for head and neck cancer
11. Clemson University spin-off uses corn to make plastics, provide cleaner air

Post Your Comments:
(Date:11/4/2014)... the right amount of death at the right time ... to new research that could help in understanding animal ... , In a paper in the journal Trends ... and European colleagues conclude that the kind of positive ... of individuals, or mortality, depends on the size and ...
(Date:11/4/2014)... 2014) – A majority of Madagascar,s 101 species of ... serious consequences for the rainforests they call home. A ... impacts lemurs can have on rainforest tree populations, which ... have on the region,s rich biodiversity. , A large ... by lemurs. Lemurs in turn disperse the seeds ...
(Date:11/3/2014)... that low birth weight and preterm birth are linked ... adulthood. Findings published in the American College of Rheumatology ... that low birth weight and pre-term babies were not ... as adults. , According to the ACR, 27 ... with clinical OA. Symptoms of OA range from mild ...
Breaking Biology News(10 mins):When less is more: Death in moderation boosts population density in nature 2Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3Preterm, low birth-weight babies may need new hips in adulthood 2
(Date:11/21/2014)... November 20, 2014 The ... Chassis, Oligos, Enzymes, Cloning kits), Technology (Bioinformatics, ... (Biofuels, Pharmaceuticals, Biomaterials, Bioremediation) - Global Forecast ... market drivers, threats, opportunities, and challenges. , ... figures spread through 185 pages and in-depth ...
(Date:11/21/2014)... (PRWEB) November 20, 2014 BlueInGreen, ... Ozone Solutions, LLC (Pinnacle), and PCI, Inc., leading ... that they have been selected to provide a ... Fayetteville, Arkansas Paul R. Noland Wastewater Treatment. ... patented HyDOZ® gas dissolution technology, Pinnacle ...
(Date:11/21/2014)... 2014 Deep Research Report on Global ... and in-depth research report on the Sodium ferrocyanide ... its definition, classification, application, and industry chain structure ... the international market analysis, including China’s domestic market ... Europe, Asia, China, Japan etc. regions) industry analysis ...
(Date:11/21/2014)... , Nov. 20, 2014 Polaris Group ... dosed in its Phase 1 trial of ADI-PEG ... the treatment of malignant pleural mesothelioma (MPM) and ... conducting clinical trials on ADI-PEG 20, both as ... the treatment of several other indications, including breast ...
Breaking Biology Technology:Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 2Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 4City of Fayetteville Leads Nation with Innovative Ozone Technology 2City of Fayetteville Leads Nation with Innovative Ozone Technology 3City of Fayetteville Leads Nation with Innovative Ozone Technology 4Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2
Cached News: